NO801428L - Krystalliserte cefalosporinsalter og fremgangsmaate til deres fremstilling - Google Patents
Krystalliserte cefalosporinsalter og fremgangsmaate til deres fremstillingInfo
- Publication number
- NO801428L NO801428L NO801428A NO801428A NO801428L NO 801428 L NO801428 L NO 801428L NO 801428 A NO801428 A NO 801428A NO 801428 A NO801428 A NO 801428A NO 801428 L NO801428 L NO 801428L
- Authority
- NO
- Norway
- Prior art keywords
- acid
- crystalline
- compound
- preparation
- salt
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title description 10
- HOKIDJSKDBPKTQ-UHFFFAOYSA-N 3-(acetyloxymethyl)-7-[(5-amino-5-carboxypentanoyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical class S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C(NC(=O)CCCC(N)C(O)=O)C12 HOKIDJSKDBPKTQ-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 10
- 239000011975 tartaric acid Substances 0.000 claims description 9
- 235000002906 tartaric acid Nutrition 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- -1 pivaloyloxymethyl Chemical group 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims 2
- 239000013078 crystal Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 238000000634 powder X-ray diffraction Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 6
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000002198 insoluble material Substances 0.000 description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- PELJISAVHGXLAL-UHFFFAOYSA-N iodomethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCI PELJISAVHGXLAL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/36—Methylene radicals, substituted by sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5948179A JPS55151588A (en) | 1979-05-14 | 1979-05-14 | Preparation of cephalosporin salt crystal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO801428L true NO801428L (no) | 1980-11-17 |
Family
ID=13114535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO801428A NO801428L (no) | 1979-05-14 | 1980-05-13 | Krystalliserte cefalosporinsalter og fremgangsmaate til deres fremstilling |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4316018A (it) |
| JP (1) | JPS55151588A (it) |
| AT (1) | AT367427B (it) |
| AU (1) | AU5838080A (it) |
| BE (1) | BE883250A (it) |
| DE (1) | DE3018340A1 (it) |
| DK (1) | DK209380A (it) |
| ES (1) | ES491386A0 (it) |
| FI (1) | FI801563A (it) |
| FR (1) | FR2456746A1 (it) |
| GB (1) | GB2052483A (it) |
| GR (1) | GR68203B (it) |
| IT (1) | IT1132053B (it) |
| NL (1) | NL8002758A (it) |
| NO (1) | NO801428L (it) |
| NZ (1) | NZ193634A (it) |
| PT (1) | PT71241B (it) |
| SE (1) | SE8003548L (it) |
| SU (1) | SU973024A3 (it) |
| ZA (1) | ZA802874B (it) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR78221B (it) * | 1980-02-01 | 1984-09-26 | Ciba Geigy Ag | |
| US4616008A (en) * | 1984-05-02 | 1986-10-07 | Takeda Chemical Industries, Ltd. | Antibacterial solid composition for oral administration |
| FR2585705B1 (fr) * | 1985-08-05 | 1989-01-13 | Bristol Myers Co | Sels de cephalosporine et compositions injectables |
| US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| US4910301A (en) * | 1985-08-05 | 1990-03-20 | Bristol-Myers Company | Cefepime cephalosporin salts |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS603314B2 (ja) * | 1976-08-31 | 1985-01-26 | 武田薬品工業株式会社 | セフアロスポリン誘導体およびその製造法 |
| US4189479A (en) * | 1977-12-22 | 1980-02-19 | Takeda Chemical Industries, Ltd. | Cephalosporin esters |
-
1979
- 1979-05-14 JP JP5948179A patent/JPS55151588A/ja active Pending
-
1980
- 1980-05-03 GR GR61865A patent/GR68203B/el unknown
- 1980-05-06 NZ NZ193634A patent/NZ193634A/xx unknown
- 1980-05-06 US US06/147,053 patent/US4316018A/en not_active Expired - Lifetime
- 1980-05-12 SE SE8003548A patent/SE8003548L/ not_active Application Discontinuation
- 1980-05-12 ES ES491386A patent/ES491386A0/es active Granted
- 1980-05-13 DE DE19803018340 patent/DE3018340A1/de not_active Withdrawn
- 1980-05-13 GB GB8015741A patent/GB2052483A/en not_active Withdrawn
- 1980-05-13 BE BE1/9820A patent/BE883250A/fr unknown
- 1980-05-13 DK DK209380A patent/DK209380A/da unknown
- 1980-05-13 NO NO801428A patent/NO801428L/no unknown
- 1980-05-13 NL NL8002758A patent/NL8002758A/nl not_active Application Discontinuation
- 1980-05-13 IT IT22020/80A patent/IT1132053B/it active
- 1980-05-14 ZA ZA00802874A patent/ZA802874B/xx unknown
- 1980-05-14 FI FI801563A patent/FI801563A/fi not_active Application Discontinuation
- 1980-05-14 AU AU58380/80A patent/AU5838080A/en not_active Abandoned
- 1980-05-14 FR FR8010921A patent/FR2456746A1/fr not_active Withdrawn
- 1980-05-14 SU SU802921250A patent/SU973024A3/ru active
- 1980-05-14 AT AT0259180A patent/AT367427B/de not_active IP Right Cessation
- 1980-05-14 PT PT71241A patent/PT71241B/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES8102132A1 (es) | 1980-12-16 |
| IT8022020A0 (it) | 1980-05-13 |
| US4316018A (en) | 1982-02-16 |
| SE8003548L (sv) | 1980-11-15 |
| IT1132053B (it) | 1986-06-25 |
| DK209380A (da) | 1980-11-15 |
| FR2456746A1 (fr) | 1980-12-12 |
| PT71241B (en) | 1982-06-08 |
| FI801563A (fi) | 1980-11-15 |
| DE3018340A1 (de) | 1980-11-27 |
| ATA259180A (de) | 1981-11-15 |
| ES491386A0 (es) | 1980-12-16 |
| PT71241A (en) | 1980-06-01 |
| AT367427B (de) | 1982-07-12 |
| NL8002758A (nl) | 1980-11-18 |
| JPS55151588A (en) | 1980-11-26 |
| GB2052483A (en) | 1981-01-28 |
| BE883250A (fr) | 1980-11-13 |
| ZA802874B (en) | 1980-12-31 |
| SU973024A3 (ru) | 1982-11-07 |
| NZ193634A (en) | 1982-05-25 |
| GR68203B (it) | 1981-11-10 |
| AU5838080A (en) | 1980-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1480766A3 (ru) | Способ получени кристаллического торасемида | |
| BRPI0509595B1 (pt) | Processos para a preparação de cristais de forma a e de material de padrão c de bissulfato de atazanavir | |
| DK155525B (da) | Fremgangsmaade til fremstilling af (6r,7r)-7-oe(z)-2-(2-aminotiazol-4-yl)-2-(2-karboxyprop-2-oxyimino)-acetamidoaa-3-(1-pyridiniummetyl)-ceph-3-em-4-karboxylat-pentahydrat | |
| JPH0257072B2 (it) | ||
| JPH0346474B2 (it) | ||
| CA1335590C (en) | Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide | |
| NO801428L (no) | Krystalliserte cefalosporinsalter og fremgangsmaate til deres fremstilling | |
| JPS64396B2 (it) | ||
| SU845789A3 (ru) | Способ получени -7- -(4-окси-6-метил-НиКОТиНАМидО)- -(4-ОКСифЕНил)АцЕТАМидО -3- (1-МЕТилТЕТРАзОл-5-ил)ТиОМЕТил-3-цЕфЕМ-4-КАРбО-НОВОй КиСлОТы | |
| FI80274B (fi) | Foerfarande foer framstaellning av antibiotiskt aktivt kristallint monohydrat av cefalexinhydroklorid och ett alkanolsolvat som anvaends som utgaongsaemne i foerfarandet. | |
| JP2002326993A (ja) | β−ラクタム化合物の無水結晶及びその製造法 | |
| JP2007238596A (ja) | アミノ酸の二塩酸塩の生成のための直接的なプロセス | |
| JPH05222056A (ja) | セファロスポリン抗生物質の結晶性形状 | |
| JP2723088B2 (ja) | セファロスポリン化合物の新規な結晶 | |
| KR100912214B1 (ko) | 세프디니르 세슘 염의 결정형 | |
| NO140269B (no) | Analogifremgangsmaate for fremstilling av terapeutisk virksomme cefalosporinderivater | |
| US4594417A (en) | Crystalline antibiotic salt | |
| JP3755908B2 (ja) | セファロスポリン化合物の晶析法 | |
| JPS636552B2 (it) | ||
| JP2575590B2 (ja) | トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法 | |
| JP2004518683A (ja) | ３−（３−アミジノフェニル）−５−［（｛〔１−（１−イミノエチル）−４−ピペリジル〕メチル｝アミノ）メチル］安息香酸二塩酸塩およびその製造方法 | |
| EP0078671A2 (en) | Novel cephalosporin salt and its use in a purification process | |
| JP3931884B2 (ja) | 錠剤の製造方法 | |
| JPS6052751B2 (ja) | 新規な結晶形を有するセフアレキシン１水和物 | |
| IE43666B1 (en) | Cephalosporins |